Adherence of Option B+ prevention of mother-to-child transmission program and its associated factors among pregnant and lactating mothers in public health facilities of East Gojjam zone, Amhara region, Ethiopia, 2017

Abstract

<p class="abstract"><strong>Background:</strong> Adherence of antiretroviral treatment (ART) among women on prevention of mother-to-child transmission (PMTCT) program is a central component to reduce viral loads and achieve elimination of mother to child transmission of human immunodeficiency virus (HIV) to Ethiopia. Option B+ PMTCT program is a recently introduced approach to eliminate new HIV infection among child. There is limited evidence on the drug adherence of women on ART in the Option B+ strategy. The aim was to assess adherence of Option B+ PMTCT drug and its associated factors among pregnant & lactating mothers in health facilities of East Gojjam zone, Amhara, Ethiopia, 2017.</p><p class="abstract"><strong>Methods:</strong> Institution based cross-sectional study design was conducted from randomly selected three public health facilities in East Gojjam zone. Data was entered in to Epi data 3.1 and cleared then transferred to SPSS version 20 for analysis. To assess the associated factors, logistic regression model was employed. A p value <0.05 was considered statistically significant. </p><p class="abstract"><strong>Results:</strong> Adherence on Option B+ PMTCT drug was 75%. The likelihood of being adherence found to be significant association with the following variables: Mother’s educational status (AOR=2.03; 95%CI: 1.465, 8.918), partner occupation (AOR=4.73; 95%CI: 1.12, 19.87), time to reach to health facility (AOR=0.21; 95%CI: 0.05, 0.824), and maternal HIV knowledge (AOR=0.13; 95%CI: 0.03, 0.44).</p><strong>Conclusions:</strong> Adherence to Option B+ PMTCT drug in East Gojjam zone, Amhara region was low compared to the national goal. Effort should be made both governmentally as well as non- governmentally to advance the knowledge about Option B+ PMTCT program so as to improve the long term maternal and child health.

Adherence to option B+ PMTCT program and its predictors among HIV‐positive women in Ethiopia. A systematic review and meta‐analysis

“…The sample size of included studies ranged from 103 31 to 350 14 . Six of the studies, 20,31–35 involved only HIV‐positive pregnant women whereas the remaining six studies, 13,14,19,25,36,37 included both pregnant and lactating mothers living with HIV. Adherence was measured by the self‐report method in eight studies 13,14,19,20,32–35 .…”

“…The magnitude of adherence to option B+ PMTCT among HIV‐positive pregnant and lactating women was our primary outcome of interest. There are several methods to measure adherence; commonly it can be measured by the self‐report method, pill count method, or else a combination of these methods can also be employed 23–25 . Secondly, factors associated with adherence to option B+ PMTCT were identified.…”

“…13,14,19,20,[32][33][34][35] Whereas the remaining four studies employed both self-report and pill count methods to measure adherence. 25,31,36,37 Primary studies reported that adherence to option B+ PMTCT ranges from 66.02% 31 to 88.19% 13 (Table 1).…”

“…There are several methods to measure adherence; commonly it can be measured by the self-report method, pill count method, or else a combination of these methods can also be employed. [23][24][25] Secondly, factors associated with adherence to option B+ PMTCT were identified.…”

<p>Level of Good Adherence on Option B+ PMTCT and Associated Factors Among HIV Positive Pregnant and Lactating Mothers in Public Health Facilities of Ilu Abba Bor and Buno Bedele Zones, Oromia Regional State, Southwestern Ethiopia, 2018</p>

“…Similarly, this finding was higher than a study done in Tanzania, East Gojjam zone, and western Uganda showing Good adherence to option B+ PMTCT drugs of 26.3%, 75%, and 51% respectively. [20][21][22] This difference might be, because of the difference in study setting like a study done in western Uganda measures the adherence level only for postpartum women.…”